Compare FCN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCN | ERAS |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.0B |
| IPO Year | 1996 | 2021 |
| Metric | FCN | ERAS |
|---|---|---|
| Price | $149.66 | $18.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $165.00 | $14.25 |
| AVG Volume (30 Days) | 409.9K | ★ 3.2M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 5.51 | ★ 36.23 |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $3,788,857,000.00 | N/A |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | $38.51 | ★ N/A |
| Revenue Growth | ★ 2.44 | N/A |
| 52 Week Low | $137.65 | $1.33 |
| 52 Week High | $189.30 | $24.28 |
| Indicator | FCN | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 53.18 |
| Support Level | $139.24 | $17.36 |
| Resistance Level | $166.98 | $19.96 |
| Average True Range (ATR) | 5.44 | 0.99 |
| MACD | -0.93 | -0.12 |
| Stochastic Oscillator | 3.65 | 67.76 |
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.